Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

282 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

NCT00448422

Acute Bacterial Gastroenteritis

COMPLETED PHASE3

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

NCT00098384

Diarrhea

COMPLETED PHASE2

Rifaximin for Prevention of Travellers' Diarrhea

NCT00742469

Diarrhea

COMPLETED PHASE3

Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea

NCT01070277

Chronic Diarrhea Abdominal Pain Bloating

UNKNOWN NA

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

NCT03535272

Diarrhea Travelers Antibiotic Resistant Infection

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double-blind trial will compare the safety and efficacy of prulifloxacin versus placebo in adult travelers with acute gastroenteritis characterized by diarrhea with one or more of the following signs or symptoms: nausea, vomiting, abdominal pain or cramping, fecal urgency, moderate to severe gas-related symptoms, or tenesmus of ≤72 hours duration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Gastroenteritis in Adult Travelers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Prulifloxacin

Group Type EXPERIMENTAL

Prulifloxacin

Intervention Type DRUG

Tablet

2

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prulifloxacin

Tablet

Intervention Type DRUG

Placebo

Tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Acute Bacterial Gastroenteritis;
* Traveler from Industrialized Country;
* Capable of giving Informed Consent

Exclusion Criteria

* Fever (\>100.3 degrees);
* Pregnant or Breast Feeding or Not using adequate birth control;
* Known or Suspected (co-)Infection with non-bacterial pathogen;
* Symptoms of Gastroenteritis of \>72 hours;
* Bloody Diarrhea;
* Concomitant antibacterial with activity against enteric bacterial pathogens;
* History of IBD;
* Unable/Unwilling to comply with study protocol;
* \> 2 doses of anti-diarrheal medication within 24 hours;
* Antimicrobial Treatment within 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No